Wellbeing Digital Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Najla Guthrie
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 1917 West 4th Avenue Vancouver BC Canada V6J 1M7
- IPO Date
- Oct 22, 2021
- Website
- ketamine.one
- Similar Companies
- Business
- Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company specializing in the development and implementation of clinical treatment solutions, including psychedelic medicines and digital therapeutics. The company offers ketamine-assisted therapy, psychedelic medicine treatment programs, and digital therapeutic products through a network of healthcare clinics across North America. Additionally, it operates a contract research organization subsidiary, KGK Sciences Inc., which provides high-quality clinical research trials, regulatory support, participant recruitment, and consulting services focused on nutraceuticals and emerging healthcare products. KGK Sciences also supports drug development through custom-designed clinical trials and claim substantiation strategies. Founded in 2017 and headquartered in Vancouver, Canada, Wellbeing Digital Sciences focuses on mental health innovation by integrating AI-enhanced digital therapeutics alongside its psychedelic medicine offerings. Recent major changes include the divestiture of its KGK Sciences subsidiary through a share purchase agreement with Cardinal Group Companies LLC in 2023, marking a strategic shift to concentrate more on core mental health therapies and clinic operations. The company also pioneered a Health Canada-authorized Phase IIA clinical trial of a psilocybin drug for fragile X syndrome, collaborating with Nova Mentis Life Science Corp., with special regulatory approval for take-home dosing. Moreover, Wellbeing Digital Sciences has rebranded from its former name KetamineOne Capital Limited to reflect its broadened focus beyond ketamine therapies to the wider field of digital and psychedelic mental healthcare. Wellbeing operates clinics providing IV ketamine therapy and services supporting clinical trial management and psychedelic research. It targets mental illness treatment markets in Canada and the U.S., leveraging a research-backed approach to innovative mental healthcare. The company's recent emphasis on expanding digital therapeutics, conducting advanced clinical trials, and engaging in strategic partnerships positions it as a next-generation wellness company focused on evidence-based psychedelic medicine and digital solutions for mental health disorders. Najla Guthrie serves as the CEO, guiding the company's evolution and participation in prominent psychedelic and healthcare industry conferences. Wellbeing Digital Sciences seeks to become a leading healthcare model in North America for mental illness treatment by advancing innovative psychedelics and digital therapeutic interventions backed by rigorous clinical research. This comprehensive approach encompassing clinical services, drug development trials, and digital therapeutics defines Wellbeing Digital Sciences Inc.'s operations and strategic focus as of late 2025.
Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group
Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial
Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout
Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study
Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial
Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome
Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license
Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response
Wellbeing Digital Sciences subsidiary KGK Science submits psilocybin and Fragile X Syndrome clinical trial application for client Nova Mentis
Wellbeing Digital Sciences says Mindscape subsidiary treats its 1,000th patient
Wellbeing Digital Sciences appoints Mohammad Sharifi to its board of directors
Wellbeing Digital Sciences says KGK Science subsidiary inks research services deal with Nova Mentis for Fragile X Syndrome clinical trials
Wellbeing Digital Sciences says KGK Science subsidiary study successfully delivers CBD and THC through the skin
Wellbeing Digital Sciences and its subsidiary KGK Sciences hail Alberta government's move to regulate psychedelics use
Wellbeing Digital Sciences subsidiary KGK Sciences to submit psilocybin microdose capsule formulation to Health Canada
Wellbeing Digital Sciences to add three well-established pain management facilities to its clinical ecosystem
Wellbeing Digital Sciences says subsidiary KGK Sciences opens new clinical research centre in Ontario
Wellbeing Digital Sciences posts fiscal 4Q results; projects significant revenue from research and consulting contracts
Wellbeing Digital Sciences says subsidiary KGK Sciences wins FDA's highest safety rating for ProGo ingredient on behalf of client Hofseth BioCare
Wellbeing Digital Sciences says subsidiary IRP Health's new Toronto clinic has received approval from Veterans Affairs Canada for its Reactivation program